- Home
- CNM vs SYRE Comparison
CNM vs SYRE Comparison
Compare CNM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNM | SYRE |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 8.5B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CNM | SYRE |
|---|---|---|
| Price | $44.06 | $90.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $61.55 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 1.8M | 1.0M |
| Earning Date | 06-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.45 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $7,647,000,000.00 | N/A |
| Revenue This Year | $4.89 | N/A |
| Revenue Next Year | $4.21 | N/A |
| P/E Ratio | $77.75 | ★ N/A |
| Revenue Growth | ★ 2.77 | N/A |
| 52 Week Low | $41.55 | $14.51 |
| 52 Week High | $59.66 | $110.18 |
Technical Indicators
Market Signals| Indicator | CNM | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 39.96 |
| Support Level | $42.19 | $66.78 |
| Resistance Level | $47.24 | $106.10 |
| Average True Range (ATR) | 1.20 | 4.49 |
| MACD | 0.02 | -1.69 |
| Stochastic Oscillator | 53.32 | 24.83 |
Price Performance
Historical ComparisonAbout CNM Core & Main Inc.
Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.